



**ASX ANNOUNCEMENT**

**12 October 2010**

### **Third VitroGro® Patent Granted in Australia**

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced the granting of a third VitroGro® patent in Australia.

Dr Steven Mercer, the CEO of Tissue Therapies said, "This patent has also been granted in Japan and examination in all other territories is progressing well. Applications for all VitroGro® patents have been lodged in the USA, EU, Canada, China, Hong Kong, Japan, South Korea, India, South Africa, Australia and New Zealand."

"The continuing success with the granting of the family of VitroGro® patents worldwide is particularly pleasing and a practical enhancement to the commercial value of Tissue Therapies."

Further information:

Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: +61 (0)7 3839 9938

Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

## About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell-based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)